U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

SKYRIZI’s new at-home regimen delivers strong remission rates for Crohn’s disease patients.

What the company is saying

AbbVie announces FDA approval for a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn’s disease, emphasizing patient flexibility and at-home treatment initiation via on-body injector. The company highlights robust efficacy from the Phase 3 AFFIRM trial, particularly in advanced therapy-naïve patients, where clinical remission reached 74% at week 12 compared to 27% for placebo. The announcement stresses that the safety profile remains consistent with prior SKYRIZI data, with no new risks identified. AbbVie also points to an FDA update allowing physicians more discretion on tuberculosis testing requirements. Executive vice president and chief scientific officer Roopal Thakkar, M.D., frames the approval as both an efficacy milestone and an advance in patient and physician choice. The narrative is confident, focusing on clinical data and regulatory progress, with only a brief mention of future clinical trial potential.

What the data suggests

The AFFIRM Phase 3 trial data show that subcutaneous SKYRIZI induction leads to markedly higher clinical remission and endoscopic response rates at week 12 versus placebo. In advanced therapy-naïve patients, clinical remission was 74% for SKYRIZI compared to 27% for placebo, and endoscopic response was 60% versus 15%. Across the total trial population, clinical remission rates were 56% for SKYRIZI and 30% for placebo, with endoscopic response at 43% versus 15%. In patients with prior advanced therapy failure, SKYRIZI achieved 45% clinical remission and 33% endoscopic response, compared to 31% and 15% for placebo, respectively. Endoscopic remission rates also favored SKYRIZI: 26% in the total population, 17% in prior therapy failures, and 43% in therapy-naïve, all outperforming placebo. The safety profile for subcutaneous induction matched previous SKYRIZI experience, with no new risks. The FDA’s concurrent update to prescribing information on TB testing adds clinical flexibility. No financial or commercial impact data are disclosed, so the analysis is limited to clinical and regulatory outcomes.

Analysis

The announcement is factual and proportionate, reporting FDA approval of a new subcutaneous induction regimen for SKYRIZI in Crohn's disease, supported by detailed Phase 3 clinical trial data. Nearly all claims are realised: the approval is granted, efficacy and safety results are disclosed with specific numerical outcomes, and the new regimen is now available for patient use. Only a single forward-looking statement references future clinical trials, which is minor and not central to the announcement. There is no mention of large capital outlays or delayed benefit realisation; the clinical and regulatory milestones are already achieved. The tone is positive but justified by the evidence, and there is no narrative inflation or exaggerated projection of future benefits. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be strong_positive, but the clinical disclosure is robust.

Risk flags

• ●Commercial uptake risk exists because the announcement provides no data on expected market penetration, pricing, or revenue impact, leaving the financial upside uncertain despite strong clinical results.
• ●Long-term safety in broader real-world populations is not addressed beyond the trial cohort, so rare adverse events or adherence issues could emerge post-launch.
• ●Competitive risk remains, as the Crohn’s disease market includes multiple advanced therapies, and the announcement does not compare SKYRIZI’s efficacy or convenience directly to other approved agents.
• ●Regulatory risk is minimal for this indication, but future label expansions or international approvals are not discussed and could face different hurdles.

Bottom line

AbbVie’s FDA approval for subcutaneous SKYRIZI induction in Crohn’s disease is underpinned by strong Phase 3 efficacy data, especially in patients new to advanced therapies, with 74% achieving clinical remission at week 12. The at-home administration option and consistent safety profile may drive adoption, but the lack of disclosed commercial projections means the financial impact is unquantified. The update to prescribing information on TB testing adds clinical flexibility but does not change the core value proposition. Investors should recognize that while the clinical and regulatory milestones are credible and immediate, the announcement does not address market size, pricing, or competitive positioning. The key takeaway is that SKYRIZI’s new regimen is now available and clinically validated, but the revenue and market share implications remain to be seen in future disclosures.

Announcement summary

(NYSE:ABBV) AbbVie announced that the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease. Patients can now initiate SKYRIZI treatment at home using an on-body injector (OBI) induction pack and continue with OBI administration every eight weeks for maintenance. The pivotal Phase 3 AFFIRM study demonstrated that SC SKYRIZI achieved superior clinical remission and endoscopic response at week 12 compared to placebo in patients with Crohn's disease. In advanced therapy-naïve patients, 74% achieved clinical remission at week 12 with SC SKYRIZI versus 27% with placebo. Endoscopic response in this group was 60% for SC SKYRIZI versus 15% for placebo. In the total AFFIRM population, clinical remission rates at week 12 were 30% for placebo and 56% for SC SKYRIZI. Among patients with prior advanced therapy failure, clinical remission was 31% for placebo and 45% for SC SKYRIZI, while in advanced therapy-naïve patients, rates were 27% for placebo and 74% for SC SKYRIZI. Endoscopic response in the total population was 15% for placebo and 43% for SC SKYRIZI; in prior advanced therapy failure patients, 15% for placebo and 33% for SC SKYRIZI; and in advanced therapy-naïve patients, 15% for placebo and 60% for SC SKYRIZI. Endoscopic remission rates in the total population were 11% for placebo and 26% for SC SKYRIZI; in prior advanced therapy failure patients, 11% for placebo and 17% for SC SKYRIZI; and in advanced therapy-naïve patients, 9% for placebo and 43% for SC SKYRIZI. The safety profile of SC SKYRIZI induction was generally consistent with its established profile in Crohn's disease, with no new safety risks identified. The FDA also approved an update to the U.S. Prescribing Information for SKYRIZI, allowing healthcare providers to use clinical judgment regarding tuberculosis (TB) testing across all indications. The AFFIRM trial enrolled a primarily treatment-refractory population, but results were particularly strong in advanced therapy-naïve patients. SC SKYRIZI also met secondary endpoints, including endoscopic remission and FACIT fatigue scores at week 12 versus placebo. SKYRIZI was administered as a 720 mg subcutaneous injection at Week 0, Week 2, Week 4, and Week 8 in the AFFIRM study. The AFFIRM study is registered as NCT06063967 on ClinicalTrials.gov. Roopal Thakkar, M.D., executive vice president, research and development, and chief scientific officer at AbbVie, stated that the approval builds on the strong efficacy of SKYRIZI and provides greater flexibility for patients and physicians.

Disagree with this article?